<DOC>
	<DOCNO>NCT00616551</DOCNO>
	<brief_summary>The purpose study assess biological safety efficacy use drug , C2L-OCT-01 PR , 30 mg treat acromegalic patient .</brief_summary>
	<brief_title>Efficacy Safety C2L-OCT-01 PR Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Subject must diagnose active acromegaly . If subject treat long act somatostatin analogue , treatment must unchanged period least 12 week prior entry . If subject treat 30 mg dose depot formulation somatostatin analogue , IGF1 level must normal entry . If subject treat 20 mg dose depot formulation somatostatin analogue , value IGF1 acceptable . If subject receive immediate release formulation somatostatin analogue dopamine agonist , IGF1 value must 10 % reference range base gender age . If subject receive dopamine agonist , must stop 14 day prior receive study medication . The subject able understand instruction , provide write consent abide study restriction . Women childbearing potential take adequate contraception pregnant lactating . Subjects previously treat growth hormone receptor antagonist ( Pegvisomant ) within 12 week study entry . Subjects undergone pituitary surgery within 6 month radiotherapy within 2 year prior admission study Subjects present form intolerance allergy test article one nonactive ingredient Subject condition alters growth hormone IGF1 level . Subjects sign symptom related tumor compression optical chiasm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>